Abstract
Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Current Pharmaceutical Design
Title: Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Volume: 17 Issue: 18
Author(s): Sylvia S. Singh and Peter M. Kang
Affiliation:
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Abstract: Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Export Options
About this article
Cite this article as:
S. Singh Sylvia and M. Kang Peter, Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390994
DOI https://dx.doi.org/10.2174/138161211796390994 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Eluting Stents in Interventional Cardiology - Current Evidence and Emerging Uses
Current Drug Targets - Cardiovascular & Hematological Disorders Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Cognitive - Behavioral Therapy in Central Sensitivity Syndromes
Current Rheumatology Reviews Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Predictors of “Worsening Renal Function” in Patients Hospitalized in Internal Medicine Department
Current Drug Safety PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry From Lizard to Snake; Behind the Evolution of an Extreme Body Plan
Current Genomics